Thanks @Pharmargeddon and @mightypirate for your links to Mk related and relevant articles both of which are squarely in the companies area of interest.
Whilst we are eagerly awaiting the outcomes of the ramping up on the Advandgen sales and potentially new distribution agreements, it is disappointing that there "appears" to be less eagerness and energy placed into Lyramid and Kinera. Is it simply a case of keeping the cards close in a competitive Biotech environment or is there a passive "wait to be contacted " approach. Isn't the 4 year CellmidZoetis agreement about to conclude. The CEO previously stated that in the absence of any notification all partnerships remain extant and ongoing. So will we see an announcement in this area in the coming months. What about the QuestLicense update ? Is this test still being developed ?
I trust there may be more detail available at the general meeting this friday.
- Forums
- ASX - By Stock
- Ann: Midkine Symposium Munich
Thanks @Pharmargeddon and @mightypirate for your links to Mk...
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online